Analyst says he’s thrown in the towel on Novo Nordisk after latest setback
Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five years.
Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five years.
Share
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
